Author: claimsbot

1. A process for treating waste sludge from a wastewater treatment plant comprising the steps of,
a) flowing the waste sludge to an anaerobic digester;
b) thickening the waste sludge before it enters the digester or recuperative thickening of digestate in the digester; and,
c) adding an external waste stream to the digester such that at least 30% of the volatile solids loading to the digester is derived from the external waste stream.
2. The process of claim 1 wherein digestate in the digester is mixed with hydraulic mixers.
3. The process of claim 1 wherein the digester is mixed intermittently.
4. The process of claim 1 comprising recuperative thickening of the digestate.
5. The process of claim 4 comprising grinding digestate before flowing the digestate to a thickener in a recuperative thickening loop.
6. The process of claim 1 comprising wasting digestate directly from the digester.
7. The process of claim 1 wherein digestate in the digester is maintained at a solids content of 3% or more.
8. The process of claim 1 wherein digestate in the digester is maintained at a solids content of 5% or more.
9. A process for treating waste sludge from a wastewater treatment plant comprising the steps of,
a) flowing the waste sludge to an existing anaerobic digester of the wastewater treatment plant; and,
b) recuperative thickening digestate in the digester.
wherein diqestate in the digester is maintained at a solids content of 5% or more, and further comprising adding an external waste stream to the digester such that at least 30% of the volatile solids loading to the digester is derived from the external waste stream.
10. The process of claim 9 wherein the step of recuperative thickening comprises thickening digestate in a rotary screw press.
11. The process of claim 9 comprising mixing digestate in the digester with a hydraulic mixer.
12. A process for treating waste sludge from a wastewater treatment plant comprising the steps of,
a) flowing the waste sludge to an existing anaerobic digester of the wastewater treatment plant; and,
b) recuperative thickening digestate in the digester,
wherein digestate in the digester is maintained at a solids content of 5% or more, and further comprising mixing digestate in the digester intermittently.
13. The process of claim 12 wherein the step of recuperative thickening comprises thickening digestate in a rotary screw press.
14. The process of claim 12 comprising mixing digestate in the digester intermittently.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An imidazole compound represented by the formula (I):
wherein
ring A is a pyridine ring optionally having substituents selected from
(1) C1-6 alkyl group, and
(2) C1-6 alkoxy group optionally substituted by substituent(s) selected from halogen atom(s) and C1-6 alkoxy group,

ring B is a benzene ring optionally having substituents selected from
C1-6 alkoxy group optionally substituted by halogen atom(s),

X1 and X2 are each an oxygen atom or a sulfur atom,
W is a C1-6 alkylene group optionally having substituents selected from C1-6 alkyl-carbonyloxy and ethoxycarbonyloxy or a divalent group represented by the formula:
\u2014W1-Z-W2\u2014
\u2003wherein W1 and W2 are each a C1-6 alkylene group or a bond, Z is C6-14 arene, an oxygen atom, SOn wherein n is 0, 1 or 2, or >N-E wherein E is a hydrogen atom, a lower alkanoyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, a thiocarbamoyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a sulfamoyl group, a mono-lower alkylsulfamoyl group, a di-lower alkylsulfamoyl group, an arylsulfamoyl group, an arylsulfinyl group, an arylsulfonyl group, an arylcarbonyl group or a carbamoyl group, and when Z is an oxygen atom, SOn or >N-E, W1 and W2 are each C1-6 alkylene group,
R is a group selected from
(1) C1-6 alkyl group optionally substituted by C1-6 alkyl-carbonyloxy,
(2) C3-10 cycloalkyl group, and
(3) C6-14 aryl group optionally substituted by a group represented by \u2014CO\u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group),

D1 is an oxygen atom, a sulfur atom or >NR1,
D2 is a bond, an oxygen atom, a sulfur atom or >NR1 wherein each R1 is independently C1-6 alkyl group, and
Y is a group selected from
(1) C1-6 alkyl group optionally having substituent(s) selected from C1-6 alkoxy group, ethoxycarbonyloxy group, C6-14 aryl group and a group represented by \u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group),
(2) C3-10 cycloalkyl group,
(3) C6-14 aryl group optionally having substituent(s) selected from (i) halogen atom and (ii) C1-6 alkoxy group optionally having halogen atom(s), and
(4) tetrahydropyran,
or a salt thereof.
2. The compound of claim 1, wherein Z is C6-14 arene.
3. The compound of claim 1, which is represented by the formula (II):
wherein each symbol in the formula is as defined in claim 1.
4. The compound of claim 1 wherein X1 and X2 are each an oxygen atom.
5. The compound of claim 1, wherein D1 is an oxygen atom and D2 is a bond or an oxygen atom.
6. The compound of claim 1, wherein W is a divalent chain C1-6 alkylene group optionally having substituents selected from C1-6 alkyl-carbonyloxy and ethoxycarbonyloxy.
7. The compound of claim 1, wherein W is an ethylene group.
8. The compound of claim 1, wherein Y is a group selected from
(1) C1-6 alkyl group optionally having substituent(s) selected from C1-6 alkoxy group, ethoxycarbonyloxy group, C6-14 aryl group and a group represented by \u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group),
(2) C3-10 cycloalkyl group, and
(3) C6-14 aryl group optionally having substituent(s) selected from (i) halogen atom and (ii) C1-6 alkoxy group optionally having halogen atom(s).
9. The compound of claim 1, wherein X1 and X2 are each an oxygen atom, D1 is an oxygen atom and D2 is a bond or an oxygen atom, W is an ethylene group, R is a C1-6 alkyl group, and Y is a group selected from (1) C1-6 alkyl group optionally having substituent(s) selected from C1-6 alkoxy group, ethoxycarbonyloxy group, C6-14 aryl group and a group represented by \u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group), (2) C3-10 cycloalkyl group, and (3) C6-14 aryl group optionally having substituent(s) selected from (i) halogen atom and (ii) C1-6 alkoxy group optionally having halogen atom(s).
10. The compound of claim 1, which is a compound selected from 2-methyl(R)-2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1H-benzimida zol-1-ylcarbonylaminoethyl acetate, ethyl 2-methyl(R)-2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1H-benzimidazol-1-ylcarbonylaminoethyl carbonate, 2-methyl(R)-2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1H-benzimida zol-1ylcarbonylaminoethyl tetrahydropyran-4-yl carbonate, 2-methyl2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1 H-benzimidazol-1-ylcarbonylaminoethyl tetrahydropyran-4-yl carbonate, ethyl 2-methyl2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1H-benzimi dazol-1-ylcarbonylaminoethyl carbonate, ethyl 2-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl-3H-imidazo4,5-bpyridin-3-ylcarbonyl(methyl)aminoethyl carbonate, 2-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl-3H-imidazo4,5-bpyrid in-3-ylcarbonyl(methyl)aminoethyl acetate, 2-methyl2-3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinyl-1H-benzimidazol-1-ylcarbonylaminoethyl acetate, ethyl 2-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl-1H-benzimidazol-1-ylcarbonyl(methyl)aminoethyl carbonate, ethyl 2-(S)-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl-1H-benzimida zol-1-ylcarbonyl(methyl)aminoethyl carbonate, ethyl 2-2-4-(3-methoxypropoxy)-3-methyl-2-pyridylmethylsulfinyl-1H-benzimidazol-1-ylcarbonyl(methyl)aminoethyl carbonate, and 2-5-(difluoromethoxy)-2-(3,4-dimethoxy-2-pyridyl)methylsulfinyl-1H-benzimidazol-1-ylc arbonyl(methyl)aminoethyl ethyl carbonate, or a salt thereof.
11. A production method of a compound of claim 1, which comprises (1) condensing a compound represented by the formula (III):
wherein
ring A is a pyridine ring optionally having substituents selected from
(1) C1-6 alkyl group, and
(2) C1-6 alkoxy group optionally substituted by substituent(s) selected from halogen atom(s) and C1-6 alkoxy group,

ring B is a benzene ring optionally having substituents selected from C1-6 alkoxy group optionally having halogen atom(s), and
M is a hydrogen atom, a metal cation or a quaternary ammonium ion, or a salt thereof, with a compound represented by the formula (IV):
wherein
X is a leaving group,
X1 and X2 are each an oxygen atom or a sulfur atom,
W is C1-6 alkylene group optionally having substituents selected from C1-6 alkyl-carbonyloxy and ethoxycarbonyloxy, or a divalent group of the formula:
\u2014W1-Z-W2\u2014
\u2003wherein W1 and W2 are each a C1-6 alkylene group or a bond, Z is C6-14 arene, an oxygen atom, SOn wherein n is 0, 1 or 2, or >N-E wherein E is a hydrogen atom, a lower alkanoyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, a thiocarbamoyl group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a sulfamoyl group, a mono-lower alkylsulfamoyl group, a di-lower alkylsulfamoyl group, an arylsulfamoyl group, an arylsulfinyl group, an arylsulfonyl group, an arylcarbonyl group or a carbamoyl group, and when Z is an oxygen atom, SOn or >N-E, W1 and W2 are each C1-6 alkylene group,
R is a group selected from
(1) C1-6 alkyl group optionally substituted by C1-6 alkyl-carbonyloxy,
(2) C3-10 cycloalkyl group, and
(3) C6-14 aryl group optionally substituted by a group represented by \u2014CO\u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group),

D1 is an oxygen atom, a sulfur atom, or >NR1,
D2 is a bond, an oxygen atom, a sulfur atom, or >NR1 wherein each R1 is independently C1-6alkyl group, and
Y is a group selected from
(1) C1-6alkyl group optionally having substituent(s) selected from C1-6 alkoxy group, ethoxycarbonyloxy group, C6-14 aryl group and a group represented by \u2014NR2R3 (wherein R2 and R3 are each C1-6 alkyl group),
(2) C3-10 cycloalkyl group,
(3) C6-14 aryl group optionally having substituent(s) selected from (i) halogen atom and (ii) C1-6 alkoxy group optionally having halogen atom(s), and
(4) tetrahydropyran, or

a salt thereof.
12. A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier.
13. A method for the treatment of peptic ulcer in an animal, which comprises administering an effective amount of a compound of claim 1 to the animal.

1. A method for packaging a multi-chip module, comprising the steps of:
(a) connecting connection terminals of a tape of an anisotropic conductive adhesive film, on which a circuit is patterned to bond pads of a chip by applying a first anisotropic conductive adhesive on the tape and using a first C4 process;
(b) applying an adhesive on an upper surface of the chip, folding the tape and attaching the folded tape to the upper surface of the chip;
(c) forming a plurality of ball terminals on a lower surface of the tape, the ball terminals being electrically connected to the connection terminals of the tape;
(d) manufacturing a plurality of individual chip scale packages by repeating the steps (a) to (c); and
(e) laminating the individual chip scale packages, wherein the ball terminals of an upper individual chip scale package are electrically connected to the circuit on an outer surface of the tape which covers a lower individual chip scale package.
2. The method of claim 1, further comprising the step of mounting the ball terminals of a lowest of the individual chip scale packages on a patterned circuit.
3. The method of claim 1, wherein, in the step (b), the adhesive comprises a second anisotropic conductive adhesive.
4. The method of claim 1, further comprising the step of providing an uppermost chip scale package on top of the laminated chip scale packages of step (e), wherein the tape covers only a lower surface of the uppermost individual chip scale package.
5. The method of claim 4, wherein the step of providing an uppermost chip scale package comprises connecting connection terminals of a further tape of a further anisotropic conductive adhesive film on which a further circuit is patterned to bond pads of a further chip by applying a second adhesive on the tape, and forming a further plurality at ball terminals on a lower surface of the further tape, the further plurality of ball terminals being electrically connected to the connection terminals of the further tape.
6. The method of claim 5, wherein the second adhesive comprises a third anisotropic conductive adhesive.
7. The method of claim 5, wherein the step of connecting the connection terminals of the further tape uses a second C4 process.
8. The method of claim 1, comprising the step of patterning the circuit on the tape.
9. The method of claim 1, wherein, in the step (b), the adhesive comprises a thermal conductive adhesive.
10. The method of claim 2, wherein the patterned circuit comprises a printed circuit board.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A magnetic resonance imaging system comprising:
a signal acquiring device for acquiring a magnetic resonance signal;
an image generating device for generating an image, based on the magnetic resonance signal;
an operating device for controlling a frame rate of the image; and
an adjusting device for adjusting a signal acquiring condition of said signal acquiring device according to the frame rate.
2. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is the number of times that a magnetic resonance signal for the same view is acquired.
3. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is the number of views for acquiring a magnetic resonance signal.
4. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is a cycle period of a pulse sequence for acquiring a magnetic resonance signal.
5. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is an echo time for a magnetic resonance signal.
6. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is the size of a single central area at the time that a k space is partitioned into the single central area and a plurality of peripheral areas and data is updated in the central area with frequency higher than the peripheral areas.
7. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is the partitioned number of peripheral areas at the time that a k space is partitioned into a single central area and a plurality of peripheral areas and data is updated in the central area with frequency higher than the peripheral areas.
8. The magnetic resonance imaging system according to claim 1, wherein the signal acquiring condition is the number of turnovers of a trajectory in a k space and the number of turns thereof at the time that a magnetic resonance signal is acquired according to a pulse sequence for echo planarimaging.
9. A recording medium having recorded therein programs for causing a computer to execute a signal acquiring function for acquiring a magnetic resonance signal;
an image generating function for generating an image, based on the magnetic resonance signal;
an operating function for controlling a frame rate of the image; and
an adjusting function for adjusting a signal acquiring condition for said signal acquiring function according to the frame rate,
said programs being recorded therein so as to be readable by the computer.
10. The recording medium according to claim 9, wherein the signal acquiring condition is the number of times that a magnetic resonance signal for the same view is acquired.
11. The recording medium according to claim 9, wherein the signal acquiring condition is the number of views for acquiring a magnetic resonance signal.
12. The recording medium according to claim 9, wherein the signal acquiring condition is a cycle period of a pulse sequence for acquiring a magnetic resonance signal.
13. The recording medium according to claim 9, wherein the signal acquiring condition is an echo time for a magnetic resonance signal.
14. The recording medium according to claim 9, wherein the signal acquiring condition is the size of a single central area at the time that a k space is partitioned into the single central area and a plurality of peripheral areas and data is updated in the central area with frequency higher than the peripheral areas.
15. The recording medium according to claim 9, wherein the signal acquiring condition is the partitioned number of peripheral areas at the time that a k space is partitioned into a single central area and a plurality of peripheral areas and data is updated in the central area with frequency higher than the peripheral areas.
16. The recording medium according to claim 9, wherein the signal acquiring condition is the number of turnovers of a trajectory in a k space and the number of turns thereof at the time that a magnetic resonance signal is acquired according to a pulse sequence for echo planarimaging.
17. A magnetic resonance imaging method comprising the steps of:
acquiring a magnetic resonance signal;
generating an image based on the magnetic resonance signal;
controlling a frame rate of the image; and
adjusting a signal acquiring condition according to the frame rate.